耐受性-话题@MedSci

#耐受性#

144篇内容 | 4029人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1417637, encodeId=a8d4141e6377a, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet Respir Med：利奥西呱治疗慢性血栓栓塞性肺动脉高压的安全性耐受性研究, objectType=article, longId=71165, objectId=4c9de1165f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4c9de1165f8, replyNumber=0, likeNumber=64, createdTime=2016-06-19, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4c9de1165f8, moduleTitle=Lancet Respir Med：利奥西呱治疗慢性血栓栓塞性肺动脉高压的安全性耐受性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4c9de1165f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417636, encodeId=a1d7141e636b4, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Cell：母乳喂养新益处！让新生儿对有益肠道细菌产生耐受性, objectType=article, longId=67731, objectId=af226e73197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af226e73197, replyNumber=0, likeNumber=87, createdTime=2016-05-09, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af226e73197, moduleTitle=Cell：母乳喂养新益处！让新生儿对有益肠道细菌产生耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af226e73197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417635, encodeId=54d8141e63578, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Nat Microbiol：细菌对抗抗生素治疗新策略---多药耐受性, objectType=article, longId=64632, objectId=1072646328c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1072646328c, replyNumber=0, likeNumber=39, createdTime=2016-03-12, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1072646328c, moduleTitle=Nat Microbiol：细菌对抗抗生素治疗新策略---多药耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1072646328c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417634, encodeId=a9b9141e634b7, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, objectType=article, longId=64211, objectId=be266421184, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be266421184, replyNumber=0, likeNumber=56, createdTime=2016-03-08, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be266421184, moduleTitle=Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=be266421184)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417633, encodeId=b6ff141e63338, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=NEJM：个体化癌症疗法或帮助抵御肿瘤对靶向药物的耐受性, objectType=article, longId=61274, objectId=2502612e461, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2502612e461, replyNumber=0, likeNumber=58, createdTime=2015-12-31, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2502612e461, moduleTitle=NEJM：个体化癌症疗法或帮助抵御肿瘤对靶向药物的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2502612e461)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417632, encodeId=0ad0141e6322b, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Mol Oncol：人工智能预测乳腺癌对化疗的耐受性，助力个体化治疗, objectType=article, longId=56648, objectId=acbc56648ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=acbc56648ff, replyNumber=0, likeNumber=64, createdTime=2015-09-29, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=acbc56648ff, moduleTitle=Mol Oncol：人工智能预测乳腺癌对化疗的耐受性，助力个体化治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=acbc56648ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417631, encodeId=bd96141e63158, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=JAMA：氢溴酸右美沙芬+硫酸奎尼丁治疗阿尔茨海默症的耐受性良好, objectType=article, longId=56604, objectId=9fdc56604b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fdc56604b9, replyNumber=0, likeNumber=64, createdTime=2015-09-27, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fdc56604b9, moduleTitle=JAMA：氢溴酸右美沙芬+硫酸奎尼丁治疗阿尔茨海默症的耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9fdc56604b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417630, encodeId=9bdb141e630e7, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=“淋巴瘤”为什么会产生放疗耐受性？, objectType=article, longId=50331, objectId=30445033125, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30445033125, replyNumber=0, likeNumber=68, createdTime=2015-05-08, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30445033125, moduleTitle=“淋巴瘤”为什么会产生放疗耐受性？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30445033125)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417629, encodeId=3110141e62986, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Cancer cell：癌症抗体治疗出现耐受性，怎样克服？, objectType=article, longId=49417, objectId=93324941e2e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93324941e2e, replyNumber=0, likeNumber=89, createdTime=2015-04-17, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93324941e2e, moduleTitle=Cancer cell：癌症抗体治疗出现耐受性，怎样克服？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93324941e2e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417628, encodeId=b9d3141e62861, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Diabetes Obes Metab：沙格列汀vs格列美脲在老年糖尿病中疗效与耐受性对比, objectType=article, longId=48825, objectId=cffe4882597, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cffe4882597, replyNumber=0, likeNumber=76, createdTime=2015-04-02, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cffe4882597, moduleTitle=Diabetes Obes Metab：沙格列汀vs格列美脲在老年糖尿病中疗效与耐受性对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cffe4882597)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417627, encodeId=4560141e62750, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性, objectType=article, longId=41415, objectId=a59e41415cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a59e41415cb, replyNumber=0, likeNumber=62, createdTime=2014-10-19, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a59e41415cb, moduleTitle=The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a59e41415cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417626, encodeId=cfaa141e62614, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Nature Cell Biology：乳腺癌对放射治疗产生耐受性的机制, objectType=article, longId=39401, objectId=bbf23940112, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bbf23940112, replyNumber=0, likeNumber=55, createdTime=2014-08-23, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bbf23940112, moduleTitle=Nature Cell Biology：乳腺癌对放射治疗产生耐受性的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bbf23940112)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417625, encodeId=6ba7141e62516, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Deutsch Arztebl Int：准确的诊断对于开发耐受性高血压的疗法至关重要, objectType=article, longId=37830, objectId=fb2c3e830cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb2c3e830cf, replyNumber=0, likeNumber=55, createdTime=2014-07-17, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb2c3e830cf, moduleTitle=Deutsch Arztebl Int：准确的诊断对于开发耐受性高血压的疗法至关重要, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb2c3e830cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417624, encodeId=af24141e62454, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=BJC：新型联合疗法可有效抑制耐受性肉瘤的生长, objectType=article, longId=37775, objectId=cf513e775c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf513e775c4, replyNumber=0, likeNumber=67, createdTime=2014-07-16, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf513e775c4, moduleTitle=BJC：新型联合疗法可有效抑制耐受性肉瘤的生长, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf513e775c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417623, encodeId=a503141e623b6, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Nat Rev Immunol：为何老年人对抗癌免疫疗法的耐受性较差, objectType=article, longId=27631, objectId=c6822e631d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6822e631d3, replyNumber=0, likeNumber=66, createdTime=2013-12-08, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6822e631d3, moduleTitle=Nat Rev Immunol：为何老年人对抗癌免疫疗法的耐受性较差, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6822e631d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417622, encodeId=9ed9141e622d2, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=阿斯利康公布naloxegol III期安全性和耐受性数据, objectType=article, longId=25502, objectId=c0ab2550255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0ab2550255, replyNumber=0, likeNumber=62, createdTime=2013-10-19, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0ab2550255, moduleTitle=阿斯利康公布naloxegol III期安全性和耐受性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0ab2550255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417621, encodeId=d3c6141e6218c, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=NEJM：ST2能作为治疗耐受性GVHD和死亡的分子标志物, objectType=article, longId=23018, objectId=9af323018ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9af323018ce, replyNumber=0, likeNumber=105, createdTime=2013-08-17, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9af323018ce, moduleTitle=NEJM：ST2能作为治疗耐受性GVHD和死亡的分子标志物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9af323018ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417620, encodeId=0f30141e62058, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=AP&T：猪鞭虫卵子对克罗恩病患者的安全性和耐受性, objectType=article, longId=22700, objectId=a13522e0087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a13522e0087, replyNumber=0, likeNumber=57, createdTime=2013-08-08, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a13522e0087, moduleTitle=AP&T：猪鞭虫卵子对克罗恩病患者的安全性和耐受性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a13522e0087)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417619, encodeId=51ab141e61961, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Ann Pharmacother：加巴喷丁治疗呃逆耐受性良好, objectType=article, longId=22123, objectId=cca8221237b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cca8221237b, replyNumber=0, likeNumber=69, createdTime=2013-07-28, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cca8221237b, moduleTitle=Ann Pharmacother：加巴喷丁治疗呃逆耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cca8221237b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1417618, encodeId=87cf141e61818, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, objectTitle=Neurology：Pridopidine治疗亨廷顿病安全性和耐受性均较好, objectType=article, longId=15925, objectId=0bd015925a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bd015925a4, replyNumber=0, likeNumber=63, createdTime=2013-03-11, rootId=0, userName=Smile2681, userId=43843300457, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bd015925a4, moduleTitle=Neurology：Pridopidine治疗亨廷顿病安全性和耐受性均较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bd015925a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

耐受性

2020-05-29

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet Respir Med：利奥西呱治疗慢性血栓栓塞性肺动脉高压的安全性耐受性研究

2016-06-19

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Cell：母乳喂养新益处！让新生儿对有益肠道细菌产生耐受性

2016-05-09

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Nat Microbiol：细菌对抗抗生素治疗新策略---多药耐受性

2016-03-12

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Lancet：PD-L1单抗Atezolizumab治疗转移性尿路上皮癌活性和耐受性良好

2016-03-08

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

NEJM：个体化癌症疗法或帮助抵御肿瘤对靶向药物的耐受性

2015-12-31

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Mol Oncol：人工智能预测乳腺癌对化疗的耐受性，助力个体化治疗

2015-09-29

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

JAMA：氢溴酸右美沙芬+硫酸奎尼丁治疗阿尔茨海默症的耐受性良好

2015-09-27

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

“淋巴瘤”为什么会产生放疗耐受性？

2015-05-08

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Cancer cell：癌症抗体治疗出现耐受性，怎样克服？

2015-04-17

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Diabetes Obes Metab：沙格列汀vs格列美脲在老年糖尿病中疗效与耐受性对比

2015-04-02

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

The Lancet Oncology：来拉度胺和利妥昔单抗联合用药对惰性非霍奇金淋巴瘤具有较好的耐受性

2014-10-19

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Nature Cell Biology：乳腺癌对放射治疗产生耐受性的机制

2014-08-23

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Deutsch Arztebl Int：准确的诊断对于开发耐受性高血压的疗法至关重要

2014-07-17

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

BJC：新型联合疗法可有效抑制耐受性肉瘤的生长

2014-07-16

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Nat Rev Immunol：为何老年人对抗癌免疫疗法的耐受性较差

2013-12-08

爆笑小医 (审核中...)

前往app查看评论内容

#耐受性#

阿斯利康公布naloxegol III期安全性和耐受性数据

2013-10-19

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

NEJM：ST2能作为治疗耐受性GVHD和死亡的分子标志物

2013-08-17

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

AP&T：猪鞭虫卵子对克罗恩病患者的安全性和耐受性

2013-08-08

docwu2019 (审核中...)

前往app查看评论内容

#耐受性#

Ann Pharmacother：加巴喷丁治疗呃逆耐受性良好

2013-07-28

Smile2681 (审核中...)

前往app查看评论内容

#耐受性#

Neurology：Pridopidine治疗亨廷顿病安全性和耐受性均较好

2013-03-11

科室
- - 订阅+
  - 更多科室
工具
服务